YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors

News
Article

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

The intracranial ORR was 28.5% among 21 evaluable patients with brain metastases at baseline and the median DOR for this subgroup was 6.2 months.

The intracranial ORR was 28.5% among 21 evaluable patients with brain metastases at baseline and the median DOR for this subgroup was 6.2 months.

YL201, a B7H3-targeting antibody drug conjugate, demonstrated an acceptable safety profile and early efficacy in adult patients with advanced solid tumors previously treated with at least 1 standard therapy, according to results from a phase 1/1b trial (NCT05434234; NCT06057922) published in Nature Medicine.

At a median follow-up of 7.5 months (95% CI, 6.5-7.9), the efficacy data from the trial revealed that among 287 patients evaluable for efficacy, the objective response rate (ORR) was 40.8% (95% CI, 35.0%-46.7%). In total, there were 2 confirmed complete responses, and 40.1% of patients experienced a confirmed partial response. A total of 42.9% of patients experienced stable disease as best response, for a disease control rate (DCR) of 83.6% (95% CI, 78.8%-87.7%) for this patient population.

Overall, the median progression-free survival (PFS) was 5.9 months (95% CI, 5.5-7.5), and the median duration of response (DOR) was 6.3 months (95% CI, 4.7-6.7). The overall survival (OS) data was not mature as of the data cut-off. The intracranial ORR was 28.5% (95% CI, 11.3%-52.2%) among 21 evaluable patients with brain metastases at baseline; the median DOR for this subgroup was 6.2 months (95% CI, 2.8-not reached [NR]).

“To our knowledge, we report here the largest cohort to date for evaluation of a B7H3-targeted ADC in patients with advanced solid tumors… YL201 demonstrated a manageable safety profile and a promising anti-tumor activity, particularly in patients with extensive-stage small cell lung cancer [ES-SCLC], nasopharyngeal cancer [NPC], or lymphoepithelioma-like carcinoma [LELC,]” Yuxiang Ma, of the Department of Clinical Research at Sun Yat-sen University Cancer Center in Guangzhou, China, wrote in the publication with study coinvestigators. “These findings provide strong confidence for the further development of YL201 in randomized trials.”

The open-label, multicenter, phase 1/1b clinical trial enrolled patients with locally advanced or metastatic solid tumors to receive YL201 monotherapy as escalating doses in the dose-escalation portion of the study or at 2.0 mg kg–1or 2.4 mg kg–1 for the dose-expansion portion. Treatment was given until disease progression, unacceptable toxicity, or withdrawal of consent in both portions of the study.

Patients on trial had a median age of 57.0 years (range, 19-87), 93.9% were Asian, and 77.6% were male. A total of 50.0% of patients were never-smokers, 85.3% had an ECOG performance score of 1, and 15.4% had brain metastases at baseline. The median number of organs with metastases was 2 (0-9).

The most common tumor types included ES-SCLC (n = 79), NPC (n = 75), wild-type non–small cell lung cancer (NSCLC; n = 68), and esophageal squamous cell carcinoma (ESCC; n = 37). The median number of prior lines of therapy was 2 (range, 1-10), with 37.2% of patients treated with 1 prior treatment line and 34.9% of patients treated with 3 or more lines of therapy. The most common prior regimens included prior platinum-based chemotherapy (92.9%), prior anti-PD-1/PD-L1 therapy (88.5%), and prior radiotherapy (60.3%).

In the phase 1 portion of the trial, the primary end point was dose-limiting toxicities during the initial cycle of study drug. The coprimary end points in the phase 1 b portion of the trial were adverse effects (AEs) and ORR. Secondary end points included pharmacokinetic parameters, DCR, DOR, PFS, best tumor response, and OS.

Treatment-related AEs (TRAEs) of any grade occurred in 97.1% of patients. The most common hematologic TRAEs included leukopenia (66.3%), anemia (64.7%), and neutropenia (61.5%). The most common non-hematologic TRAEs included anorexia (35.6%), nausea (26.3%), and hypoalbuminemia (22.8%). Furthermore, grade 3 or higher TRAEs occurred at a rate of 54.5%, with neutropenia (31.7%) being the most frequent grade 3 or higher TRAE.

Additionally, treatment-related severe AEs (SAEs) occurred in 29.2%, resulting in 5.4% of patients experiencing dose discontinuations and 17.0% experiencing dose reductions. Leukopenia was experienced as an SAE in 11.5% of patients, with a median time to first onset of 11.0 days after initiation of study treatment and a median resolution time of 7.5 days. A total of 8 (2.6%) patients died due to study treatment.

Reference

Ma Y, Yang Y, Huang Y, et al. A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat Med. 2025;31:1949-1957. doi:10.1038/s41591-025-03600-2

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Related Content